Vardenafil hydrochloride

Research use only, not for human use.

Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor in the Treatment of Erectile Dysfunction in Men With Diabetes.

Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor in the Treatment of Erectile Dysfunction in Men With Diabetes.

——

Animal Model:Male rat (9-week-old) underwent surgery for laparotomy or bilateral cavernous nerve (CN) crush injury.Dosage:0.03 mg/kg.Administration:Intravenous injectionResult:Restored normal erectile responses with a combind administration of BAY 60-4552 (0.03, 0.3 mg/kg).Animal Model:Liver injury induced by Con A in male Swiss albino mice (20 ± 2 g).Dosage:0.17 mg/kg.Administration:Intravenous injection; once daily, for 7 days; as a pretreatmentResult:Reduced the levels of serum transaminases and alleviated Con A-induced hepatitis.Animal Model:Male 7-week-old Zucker diabetic fatty (ZDF) rats (preserved ejection fraction, HFpEF) Dosage:10 mg/kg.Administration:Oral gavage; once daily, for 25 weeks Result:Improved myofilament function in diabetic rat hearts.

——

Angiogenesis

PDE

PDE5

Metabolic Disease

Erectile Dysfunction

224785-91-5

525.06

C23H33ClN6O4S

>98% (HPLC)

DMSO:100 mg/mL (190.45 mM; Need ultrasonic); H2O:100 mg/mL (190.45 mM)

Cl.CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1

——

(-20℃)

With Ice Pack

≥ 2 years